Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
Abstract Objectives To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation. Methods We retrospectively studied EGPA patients treated with mepolizumab who were on GC at the time o...
Main Authors: | Takashi Yamane, Akira Hashiramoto |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-023-03097-5 |
Similar Items
-
Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
by: Masanobu Ueno, et al.
Published: (2021-03-01) -
Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
by: Giuseppe A. Ramirez, et al.
Published: (2022-12-01) -
Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
by: Masanobu Ueno, et al.
Published: (2022-06-01) -
Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
by: Yoshiro Kai, et al.
Published: (2022-02-01) -
Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
by: Yu‐Hsuan Chen, et al.
Published: (2022-01-01)